During the past decade, National Neuroscience Institute conducted 12 clinical trials. In the 10-year time frame, 12 clinical trials started and 6 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 5 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "National Neuroscience Institute" #1 sponsor was "National Neuroscience Institute" with 6 trials, followed by "Boehringer Ingelheim" with 2 trials sponsored, "Codman & Shurtleff" with 2 trials sponsored, "TauRx Therapeutics Ltd" with 2 trials sponsored and "Astellas Pharma Inc" with 2 trials sponsored. Other sponsors include 6 different institutions and companies that sponsored additional 16 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "National Neuroscience Institute" #1 collaborator was "AegisCN LLC" with 1 trials as a collaborator, "Basilea Pharmaceutica" with 1 trials as a collaborator, "Changi General Hospital" with 1 trials as a collaborator, "Dr. Willmar Schwabe GmbH & Co. KG" with 1 trials as a collaborator and "Hovid Berhad" with 1 trials as a collaborator. Other collaborators include 6 different institutions and companies that were collaborators in the rest 16 trials.

According to Clinical.Site data, the most researched conditions in "National Neuroscience Institute" are "Stroke" (3 trials), "Stroke, Acute" (3 trials), "Alzheimer's Disease" (2 trials), "Mild Cognitive Impairment" (2 trials) and "Acute Stroke" (1 trials). Many other conditions were trialed in "National Neuroscience Institute" in a lesser frequency.

Most popular intervention types in "National Neuroscience Institute" are "Drug" (15 trials), "Device" (6 trials) and "Other" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (5 trials), "0.9% Sodium-chloride" (1 trials), "ASA 100 mg" (1 trials), "Acetyl-Valine-Serine-Arginine-Arginine-Arginine-NH2 (Ac-VSRRR- NH2)." (1 trials) and "Antiplatelet treatment" (1 trials). Other intervention names were less common.

The vast majority of trials in "National Neuroscience Institute" are 24 trials for "All" genders.

Currently, there are NaN active trials in "National Neuroscience Institute". undefined are not yet recruiting, 3 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 13 completed trials in National Neuroscience Institute, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in National Neuroscience Institute, 0 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 9 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 3 trials that are defined as “Not Applicable".